1248 related articles for article (PubMed ID: 8900370)
1. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors.
Ishida H; Matsumura T; Salgaller ML; Ohmizono Y; Kadono Y; Sawada T
Int J Cancer; 1996 Oct; 69(5):375-80. PubMed ID: 8900370
[TBL] [Abstract][Full Text] [Related]
2. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma.
Corrias MV; Scaruffi P; Occhino M; De Bernardi B; Tonini GP; Pistoia V
Int J Cancer; 1996 Oct; 69(5):403-7. PubMed ID: 8900375
[TBL] [Abstract][Full Text] [Related]
3. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
4. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR.
Jacobs JF; Brasseur F; Hulsbergen-van de Kaa CA; van de Rakt MW; Figdor CG; Adema GJ; Hoogerbrugge PM; Coulie PG; de Vries IJ
Int J Cancer; 2007 Jan; 120(1):67-74. PubMed ID: 17019710
[TBL] [Abstract][Full Text] [Related]
5. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg SA
Cancer Res; 1994 Apr; 54(7):1766-71. PubMed ID: 7511051
[TBL] [Abstract][Full Text] [Related]
6. MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.
Grau E; Oltra S; Martínez F; Orellana C; Cañete A; Fernández JM; Hernández-Martí M; Castel V
J Cancer Res Clin Oncol; 2009 Apr; 135(4):523-31. PubMed ID: 18820946
[TBL] [Abstract][Full Text] [Related]
7. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
[TBL] [Abstract][Full Text] [Related]
8. MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas.
Dalerba P; Frascella E; Macino B; Mandruzzato S; Zambon A; Rosolen A; Carli M; Ninfo V; Zanovello P
Int J Cancer; 2001 Jul; 93(1):85-90. PubMed ID: 11391626
[TBL] [Abstract][Full Text] [Related]
9. Infrequent expression of the MAGE gene family in uveal melanomas.
Mulcahy KA; Rimoldi D; Brasseur F; Rodgers S; Liénard D; Marchand M; Rennie IG; Murray AK; McIntyre CA; Platts KE; Leyvraz S; Boon T; Rees RC
Int J Cancer; 1996 Jun; 66(6):738-42. PubMed ID: 8647642
[TBL] [Abstract][Full Text] [Related]
10. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
11. Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE.
Cheung IY; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):210-2. PubMed ID: 11464887
[TBL] [Abstract][Full Text] [Related]
12. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.
Lethé B; van der Bruggen P; Brasseur F; Boon T
Melanoma Res; 1997 Aug; 7 Suppl 2():S83-8. PubMed ID: 9578421
[TBL] [Abstract][Full Text] [Related]
13. Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies.
Tanzarella S; Lionello I; Valentinis B; Russo V; Lollini PL; Traversari C
Cancer Immunol Immunother; 2004 Jun; 53(6):519-24. PubMed ID: 14727086
[TBL] [Abstract][Full Text] [Related]
14. Expression of MAGE-1 gene by esophageal carcinomas.
Toh Y; Yamana H; Shichijo S; Fujita H; Tou U; Sakaguchi M; Kakegawa T; Itoh K
Jpn J Cancer Res; 1995 Aug; 86(8):714-7. PubMed ID: 7559092
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma.
Söling A; Schurr P; Berthold F
Anticancer Res; 1999; 19(3B):2205-9. PubMed ID: 10472332
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of human neuroblastoma.
Prigione I; Corrias MV; Airoldi I; Raffaghello L; Morandi F; Bocca P; Cocco C; Ferrone S; Pistoia V
Ann N Y Acad Sci; 2004 Dec; 1028():69-80. PubMed ID: 15650233
[TBL] [Abstract][Full Text] [Related]
17. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
18. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers.
Cheung IY; Barber D; Cheung NK
Clin Cancer Res; 1998 Nov; 4(11):2801-5. PubMed ID: 9829745
[TBL] [Abstract][Full Text] [Related]
19. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T
Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731
[TBL] [Abstract][Full Text] [Related]
20. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
